Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

985812

registered interest
date	11/10/2018
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Driver and Vehicle Licensing Agency: Information Sharing
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they intend to extend the DVLA's Data Sharing Strategy to ParkTrade Europe AB and others who legitimately seek information to allow authorities in Europe to recover monies due to them from UK registered vehicle owners.
tabling member printed	Lord Kirkhope of Harrogate
uin	HL10618
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The Driver and Vehicle Licensing Agency (DVLA) takes the protection of the data it holds very seriously and has robust measures in place to protect it. The request from ParkTrade Europe is receiving careful attention and an outcome will be provided as soon as the consideration of these matters is complete.</p> answering member printed Baroness Sugg question first answered 17/10/2018 15:12:04 answering member 4584 label Biography information for Baroness Sugg
tabling member	891 label Biography information for Lord Kirkhope of Harrogate

985012

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Workers
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what estimate they have made of the number of adult social care workers required in England in the next ten years; what is the current shortfall in the number of adult social care workers in England; and what action they are taking to address that shortfall.
tabling member printed	The Marquess of Lothian
uin	HL10555
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>Skills for Care publishes data on the adult social care workforce. They estimate that 8% of roles in the adult social care sector remained vacant in 2017/18, this gives an average of approximately 110,000 vacancies at any one time. Projections show the number of adult social care jobs required will increase by 40% (650,000 jobs) to around 2.55 million jobs by 2035.</p><p>The Government is aware that our challenge, working alongside our partners in the adult social care sector, is to ensure the workforce has the right number of people to meet increasing demands, with the right skills, knowledge and values to deliver quality, compassionate care. We are looking to address the broader challenges around staff recruitment and retention in the social care market, and consulted on this issue earlier on the year. The evidence provided in the consultation responses will inform our Green Paper on the future of adult social care, with a strategy for its workforce, later this year.</p><p>In addition, the Department has announced the launch of a new adult social care recruitment campaign this autumn. This will raise the profile of the sector and help build awareness of the rich variety of roles careers on offer and attract the right people, with the right values, to deliver the very best care.</p> answering member printed Lord O'Shaughnessy question first answered 17/10/2018 15:07:06 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	259 label Biography information for The Marquess of Lothian

985013

registered interest
date	10/10/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Asylum: Families
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many applications they have received for UK visas for family settlement to reunite with a partner or parent who is in the UK as a refugee or with humanitarian protection in each year since 2010; and of those, how many have been granted.
tabling member printed	The Marquess of Lothian
uin	HL10556
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The available information is given below.</p><p>Family reunion applications from dependants of those with refugee status or humanitarian protection in the UK (made under Part 11 of the Immigration Rules) are included in the ‘Family: Other’ category within the published Home Office ‘Immigration Statistics’ visa tables, latest edition at, <a href="https://www.gov.uk/government/publications/immigration-statistics-year-ending-june-2018/list-of-tables#visas" target="_blank">https://www.gov.uk/government/publications/immigration-statistics-year-ending-june-2018/list-of-tables#visas</a>.</p><p>The vast majority of the ‘Family: Other’ category relate to family reunion and hence the published figures provide a good indication of trends for family reunion cases.</p><p>The table below provides the latest data:</p><p><strong>'Family: Other' entry clearance visa applications and outcomes: 2010 to 2017</strong></p><table><tbody><tr><td><p><strong>Year</strong></p></td><td><p><strong>Applications</strong></p></td><td><p><strong>Resolved</strong></p></td><td><p><strong>Granted</strong></p></td><td><p><strong>%</strong></p></td><td><p><strong>Refused</strong></p></td><td><p><strong>Withdrawn/Lapsed</strong></p></td></tr><tr><td><p>2010</p></td><td><p>6,111</p></td><td><p>6,654</p></td><td><p>4,887</p></td><td><p>73%</p></td><td><p>1,664</p></td><td><p>103</p></td></tr><tr><td><p>2011</p></td><td><p>5,143</p></td><td><p>5,536</p></td><td><p>4,306</p></td><td><p>78%</p></td><td><p>1,093</p></td><td><p>137</p></td></tr><tr><td><p>2012</p></td><td><p>5,135</p></td><td><p>5,318</p></td><td><p>3,710</p></td><td><p>70%</p></td><td><p>1,479</p></td><td><p>129</p></td></tr><tr><td><p>2013</p></td><td><p>6,064</p></td><td><p>6,108</p></td><td><p>4,211</p></td><td><p>69%</p></td><td><p>1,797</p></td><td><p>100</p></td></tr><tr><td><p>2014</p></td><td><p>5,639</p></td><td><p>6,658</p></td><td><p>4,596</p></td><td><p>69%</p></td><td><p>1,931</p></td><td><p>131</p></td></tr><tr><td><p>2015</p></td><td><p>8,477</p></td><td><p>8,283</p></td><td><p>4,887</p></td><td><p>59%</p></td><td><p>3,267</p></td><td><p>129</p></td></tr><tr><td><p>2016</p></td><td><p>8,610</p></td><td><p>9,620</p></td><td><p>6,098</p></td><td><p>63%</p></td><td><p>3,472</p></td><td><p>50</p></td></tr><tr><td><p>2017</p></td><td><p>7,439</p></td><td><p>7,543</p></td><td><p>5,237</p></td><td><p>69%</p></td><td><p>2,253</p></td><td><p>53</p></td></tr></tbody></table><table><tbody><tr><td><p><strong> </strong> <strong>Notes:</strong> Applications made in a given year may be resolved (granted, refused, withdrawn or lapsed) in a later year.</p></td></tr><tr><td><p><strong>Source:</strong> Home Office 'Immigration Statistics, year ending June 2018', Visas data tables volume 1, table vi_01_q.</p></td></tr></tbody></table><p> </p><p>:</p> answering member printed Baroness Williams of Trafford question first answered 17/10/2018 12:40:14 answering member 4311 label Biography information for Baroness Williams of Trafford
tabling member	259 label Biography information for The Marquess of Lothian

985031

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Special Educational Needs: Speech and Language Disorders
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they have had with Public Health England about providing practitioners with evidence-based red flags that indicate communication and language concerns at each of the statutory review points that are part of the next review of the Healthy Child Programme.
tabling member printed	Lord Ramsbotham
uin	HL10574
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The Department for Education has an ongoing dialogue with Public Health England on the issue of children’s speech and language development. They have formed a partnership to address the ‘word gap’ and support the speech, language and communication elements of the Healthy Child Programme. This programme of work will include training and resources for health visitors on speech, language and communication needs, incorporating evidence-based red flags on delayed early use of gesture and pointing by young children.</p> answering member printed Lord O'Shaughnessy question first answered 17/10/2018 15:01:17 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	3744 label Biography information for Lord Ramsbotham

985057

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what guidance is provided to NHS Trusts about the use of medication not approved by NICE to treat spinal muscular atrophy (SMA).
tabling member printed	Viscount Waverley
uin	HL10600
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL10601 HL10602 question first answered 17/10/2018 15:08:15 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf title Commissioning policy statement nusinersen
tabling member	1744 label Biography information for Viscount Waverley

985058

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of making financial resources available to patients with spinal muscular atrophy (SMA) to obtain medication not approved by NICE.
tabling member printed	Viscount Waverley
uin	HL10601
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL10600 HL10602 question first answered 17/10/2018 15:08:15 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf title Commissioning policy statement nusinersen
tabling member	1744 label Biography information for Viscount Waverley

985059

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Spinal Muscular Atrophy: Nusinersen
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what guidance is provided by NHS Trusts about making the drug Spinraza available through the NHS to patients with spinal muscular atrophy (SMA).
tabling member printed	Viscount Waverley
uin	HL10602
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of nusinersen (Spinraza) for the treatment of spinal muscular atrophy (SMA).</p><p>NHS England has published an Interim Policy Statement <em>Urgent Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP) </em>determining the circumstances in which patients will be supported to access nusinersen through the EAP scheme sponsored by Biogen, the manufacturer of nusinersen. A copy is attached. The policy statement enables patients with type 1 SMA to access nusinersen in advance of NICE’s guidance.</p><p>In the absence of final guidance from NICE, clinicians can apply to NHS England for funding in exceptional cases through the individual funding request process.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL10600 HL10601 question first answered 17/10/2018 15:08:15 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name nusinersen-for-genetically-confirmed-spinal-muscular-atrophy.pdf title Commissioning policy statement nusinersen
tabling member	1744 label Biography information for Viscount Waverley

984249

registered interest
date	09/10/2018
answering body	Women and Equalities
answering dept id	31
answering dept short name	Women and Equalities
answering dept sort name	Women and Equalities
hansard heading	Conversion Therapy
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether they plan to undertake any consultation before bringing forward proposals to ban gay conversion therapy; if so, which stakeholders they plan to consult; and what is the timetable.
tabling member printed	Lord Black of Brentwood
uin	HL10457
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>Conversion therapy is wrong and we are not willing to let it continue.</p><p> </p><p>As part of the LGBT Action Plan, we have committed to bring forward proposals to end the practice of conversion therapy in the UK. We have committed to consider all legislative and non-legislative options to prohibit promoting, offering or conducting these practices whether they are occurring in a medical, commercial or faith-based context.</p><p> </p><p>This is a complex issue that we will be approaching sensitively. We intend to engage widely before bringing forward proposals, and we will consult on the final package to ensure that the actions we take are effective and have broad support.</p> answering member printed Baroness Williams of Trafford question first answered 17/10/2018 15:19:38 answering member 4311 label Biography information for Baroness Williams of Trafford
tabling member	4171 label Biography information for Lord Black of Brentwood

984260

registered interest
date	09/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Buprenorphine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what action they are taking (1) to remedy any buprenorphine shortage, and (2) to ensure that in the long term there is consistent and adequate supply of this medication, that it is available across the country and is not subject to unpredictable price fluctuations.
tabling member printed	Lord Carlile of Berriew
uin	HL10468
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>We are aware that there was a short-term supply issue which may have affected the availability in May 2018. This was because one of the main suppliers experienced delays in delivery, resulting in a short term out of stock period. Although supplies continued to remain available from other suppliers, we are aware that some may have struggled to support the increase in demand at short notice. The delivery issues were resolved quickly and the overall supply of buprenorphine tablets improved shortly afterwards.</p><p>Since this period, the Department has remained in regular contact with all United Kingdom licensed suppliers of buprenorphine and has been working closely with them to monitor their supply position. Based on these conversations, we have been assured that the available supplies are sufficient to meet the usual UK requirements for this drug. The Department continues to monitor this very closely to ensure that there is consistent and adequate supply of this medication across the country.</p><p>The Department is aware that since this short-term supply issue, the market price has increased. This increased purchase price is reflected in the reimbursement price paid to pharmacies, to ensure that supplies remain available to patients. The market for buprenorphine has generally been competitive and we expect the supply situation to improve over the coming weeks which is likely to result in an increasingly competitive market.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 17/10/2018 15:25:57 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1138 label Biography information for Lord Carlile of Berriew

984266

registered interest
date	09/10/2018
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Museums and Galleries: Copyright
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how their policy to exploit commercially images of works of art in national museums and galleries fits with the mandates of the Arts and Humanities Research Council and other research bodies to make all publicly funded and Research Excellence Framework qualifying scholarship available on open licences from 2020 onwards.
tabling member printed	Lord Freyberg
uin	HL10474
answer	answer is ministerial correction date of answer 15/10/2018 answer text As arm’s length bodies, DCMS-sponsored museums determine their own operational matters, including the decision to charge fees for re-use of images of items in their collections - this is an operational policy matter that therefore sits with the institutions themselves. As such it is not appropriate for Government to intervene in these matters and therefore no assessment has been made, or guidance provided, on image re-use. We are currently in the process of revising performance indicators for all fifteen of the DCMS sponsored museums. We are reviewing a broad range of museum activity and government policy in order to inform our decision around which performance indicators will be selected for inclusion in the museum management agreements from 2020. We are not in a position, at this stage, to comment on specific performance indicators as the project is ongoing. The National Archives has published guidance for public sector bodies on complying with the Re-use of Public Sector Information Regulations 2015, including the attached guidance specifically for the culture sector, which can also be found here: <a href="http://www.nationalarchives.gov.uk/documents/information-management/psi-implementation-guidance-cultural-sector.pdf" target="_blank">http://www.nationalarchives.gov.uk/documents/information-management/psi-implementation-guidance-cultural-sector.pdf</a> It is each Accounting Officer's responsibility to ensure that their organisation is compliant with the terms and principles of Managing Public Money. DCMS has a governance framework in place and regularly engages with its arm’s length bodies regarding compliance issues. answering member printed Lord Ashton of Hyde grouped question UIN HL10408 HL10409 HL10410 HL10411 HL10412 HL10413 question first answered 15/10/2018 16:44:12 answering member 4247 label Biography information for Lord Ashton of Hyde attachment 1 file name psi-implementation-guidance-cultural-sector.pdf title Guidance - the Re-use of Public Sector Information
tabling member	2593 label Biography information for Lord Freyberg